JNJ-17203212

Cat. No.:	HY-100129
CAS No.:	821768-06-3
Molecular Formula:	$C_{17}H_{15}F_6N_5O$
Molecular Weight:	419.32
Target:	TRP Channel
Pathway:	Membrane Transporter/Ion Channel; Neuronal Signaling
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (238.48 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.3848 mL	11.9241 mL	23.8481 mL
	5 mM	0.4770 mL	2.3848 mL	4.7696 mL
	10 mM	0.2385 mL	1.1924 mL	2.3848 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.75 mg/mL (6.56 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.75 mg/mL (6.56 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

JNJ-17203212 is a selective, potent and competitive TRPV1 antagonist. JNJ-17203212 is developed for researching pain management, such as migraine[1][2].

IC_{50} & Target

TRPV1

In Vitro

JNJ-17203212 (0.5 μM) potently inhibits imperatorin-induced TRPV1 activation (Ca^{2+} increases) in TRPV1-expressing HEK cells[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

JNJ-17203212 (0.3 mg/kg ; i.v.) dose-dependently reduces inflammatory soup (IS)-induced the immediate early gene c-fos expression[2].

JNJ-17203212 completely blocks capsaicin-induced CGRP (the neurotransmitter calcitonin gene-related peptide) release in a dose-dependent manner[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male Sprague-Dawley rats (260-300 g)[2]
Dosage:	0.3 mg/kg
Administration:	Intravenous injection
Result:	Had a dose-dependent effect on the elevated c-fos expression that occurred after intracisternal injection of IS.

CUSTOMER VALIDATION

- EBioMedicine. 2022 Oct;84:104258.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Xingjuan Chen, et al. Furanocoumarins are a novel class of modulators for the transient receptor potential vanilloid type 1 (TRPV1) channel.J Biol Chem. 2014 Apr 4; 289(14): 9600-9610.

[2]. Jannis E Meents, et al. Two TRPV1 receptor antagonists are effective in two different experimental models of migraine. J Headache Pain. 2015; 16: 57.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA